FDA Grants Approval for Inovio's Voceryq to Treat RRP

The U.S. FDA has approved Inovio Pharmaceuticals' Voceryq (INO-3107), a plasmid DNA-based immunotherapy, for adult recurrent respiratory papillomatosis (RRP). This marks Inovio's first approved product, offering a new treatment for the rare condition that causes airway growths requiring repeated surgeries. The accelerated approval was based on a reduction in surgical papilloma excisions.